Reckitt Benckiser Group (RB) PT Set at GBX 9,000 by JPMorgan Chase & Co.

JPMorgan Chase & Co. set a GBX 9,000 ($117.60) price objective on Reckitt Benckiser Group (LON:RB) in a report issued on Wednesday morning. The firm currently has a buy rating on the stock.

A number of other research firms have also weighed in on RB. Morgan Stanley reaffirmed a buy rating on shares of Reckitt Benckiser Group in a research note on Tuesday, October 16th. Barclays reaffirmed an equal weight rating and issued a GBX 6,450 ($84.28) price objective on shares of Reckitt Benckiser Group in a research note on Tuesday, September 4th. Credit Suisse Group reaffirmed an underperform rating on shares of Reckitt Benckiser Group in a research note on Thursday, August 23rd. Goldman Sachs Group set a GBX 7,025 ($91.79) price objective on Reckitt Benckiser Group and gave the stock a neutral rating in a research note on Monday, October 8th. Finally, UBS Group upped their price objective on Reckitt Benckiser Group from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a neutral rating in a research note on Monday, September 17th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of GBX 6,999.47 ($91.46).

RB traded up GBX 51 ($0.67) during midday trading on Wednesday, reaching GBX 6,384 ($83.42). The company had a trading volume of 595,801 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 1 year low of GBX 5,562 ($72.68) and a 1 year high of GBX 8,110.43 ($105.98).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply